Jump to Navigation Back to Graphic version

Syntopix

share price

64.00p


17:13:52 (15 min delay)


Opportunities

Clinically tested anti-acne product available for licensing

A proprietary Syntopix anti-acne formulation which successfully underwent phase II cosmetic study testing to demonstrate that it was statistically better than a market leader at reducing the severity of acne.

Anti-MRSA concept available for licensing

A proprietary Syntopix anti-MRSA formulation which has been demonstrated to reduce the number of MRSA bacteria to a greater extent than the leading prophylactic treatment in vivo.

Antimicrobial compound library available for joint development

Access to a pre-screened proprietary database of antimicrobial opportunities offering a list of characterised compounds which could be instantly leveraged against multiple indications.

Consumer healthcare antimicrobial product optimisation

Syntopix has validated methodologies for the detection of beneficial compound combinations with increased antimicrobial activity for use in consumer healthcare product development or reformulation.